Bicycle Therapeutics (BCYC) Total Current Liabilities (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Total Current Liabilities of $48.9 million for Q1 2026, down 14.21% on a QoQ basis from $57.0 million in Q4 2025, and down 15.16% year-over-year from $57.6 million in Q1 2025.
Bicycle Therapeutics (BCYC) Total Current Liabilities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $48.9 million for Q1 2026.
- Quarterly Total Current Liabilities fell 15.16% year-over-year to $48.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.9 million (down 15.16% YoY) and the FY2025 annual result came in at $57.0 million, down 15.24% from the prior year.
- Total Current Liabilities was $48.9 million for Q1 2026 at Bicycle Therapeutics, down from $57.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $77.4 million in Q2 2025 and bottomed at $35.4 million in Q1 2022.
- A 5-year average of $58.2 million and a median of $57.0 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 77.64% — and 2024, when it declined 19.12%.
- Bicycle Therapeutics' Total Current Liabilities stood at $53.3 million in 2022, then jumped by 30.36% to $69.5 million in 2023, then fell by 3.32% to $67.2 million in 2024, then declined by 15.24% to $57.0 million in 2025, then fell by 14.21% to $48.9 million in 2026.
- Business Quant data shows BCYC's Total Current Liabilities at $48.9 million in Q1 2026, $57.0 million in Q4 2025, and $69.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | 48.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.89 Mn |
| Dec 31, 2025 | 56.98 Mn |
| Sep 30, 2025 | 69.28 Mn |
| Jun 30, 2025 | 77.42 Mn |
| Mar 31, 2025 | 57.62 Mn |
| Dec 31, 2024 | 67.23 Mn |
| Sep 30, 2024 | 56.41 Mn |
| Jun 30, 2024 | 69.61 Mn |
| Mar 31, 2024 | 49.51 Mn |
| Dec 31, 2023 | 69.54 Mn |
| Sep 30, 2023 | 69.74 Mn |
| Jun 30, 2023 | 72.27 Mn |
| Mar 31, 2023 | 53.00 Mn |
| Dec 31, 2022 | 53.34 Mn |
| Sep 30, 2022 | 41.55 Mn |
| Jun 30, 2022 | 41.34 Mn |
| Mar 31, 2022 | 35.41 Mn |
| Dec 31, 2021 | 36.24 Mn |
| Sep 30, 2021 | 30.18 Mn |
| Jun 30, 2021 | 23.27 Mn |